Elan Insists Remaining Alzheimer's Portfolio Has Deep Roots And New Shoots

Now that Elan has sold its immunotherapy-based drug candidates for Alzheimer's disease to Johnson & Johnson, management says it wants to focus even more intensely on the remaining pipeline, including a series of early-stage drug candidates related to Alzheimer's